TMEM219

Across TCGA pan-cancer cohorts, TMEM219 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM219 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM219 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM219 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where TMEM219 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.539	.024	11	view →
HNSC	DFS	Quartile	III,IV	0.614	0.933	.029	4	view →
LUAD	DFS	Median	All	0.832	0.961	.027	2	view →
UCEC	DFS	Median	All	1.000	0.861	.038	2	view →
PDAC	OS	Tertile	All	0.825	1.000	.049	1	view →
LSCC	DFS	Quartile	All	0.650	0.900	.032	1	view →
GBM	OS	Median	All	0.968	0.468	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM219–CCRCC (DFS)

Open the CCRCC breakdown →